Kornimate/medical-research-clean huggingface dataset:
vision response to dopamine replacement

Conditions: Albinism; Oculocutaneous Albinism

Summary: the purpose of the study is to evaluate and document physiologic and functional changes in visual performance and retinal function of patients diagnosed with albinism (a dopamine deficiency state) following a trial of oral levodopa/carbidopa treatment.

in this study the investigators propose that the retina itself in albinism is deficient in dopamine, and vision improvement will occur as a result of improved retinal function in response to the deficient neurotransmitter dopamine. this study has a pretest-posttest design in order to determine if improvement in vision is in response to replacement of deficiency (dopamine). the electroretinography (erg) testing and optical coherence tomography (oct) will be critical determinants to confirm vision improvement as a result of improved retinal function, but are not primary outcome data. main outcome measures will be collected at pre-treatment, 1 month, 3 months, and 4 months. change in visual acuity as measured in logmar by snellen or sweep visual evoked potential (svep) after 3 months of treatment is the primary outcome. patients include oca1a patients, oca1b, oca2, and unclassified oculocutaneous albinism (oca). oca1a patients clinically are known to have the worst vision, and physiologically have the lowest (or absent) levels of tyrosinase function (dopamine production). all patients will be treated with levodopa/carbidopa 4mg/kg/day in three divided doses.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of oculocutaneous albinism * age over 3 and weight over 25 lbs. exclusion criteria: * ocular only albinism * ocular pathology other than albinism * neurologic disease, history of myocardial infarction, history of clinical depression, pregnancy

Keywords: levodopa albinism dopamine oculocutaneous albinism vision retina function
the effect of cognitive orientation approach on daily occupational performance with autism spectrum disorder

Conditions: Autism Spectrum Disorder; Executive Function; Patient Participation

Summary: the goal of this clinical trial is by using the cognitive orientation approach on daily occupational performance, which is also supported by the literature and applied by occupational therapists, in children diagnosed with autism spectrum disorder, it is aimed to determine how children's executive function scores and occupational participation change. the main questions it aims to answer are: * does the cognitive orientation approach on daily occupational performance have an effect on executive functions? * does the cognitive orientation approach on daily occupational performance have an effect on occupational performance? participants will: * evaluations will be applied to all participants * divided into intervention and control groups * the intervention group will be given "cognitive orientation approach on daily occupational performance" and "ayres sensory integration therapy" followed up for about 10 weeks. * the control group will be given "ayres sensory integration therapy" followed up for about 10 weeks. * after 10 weeks, the results between the two groups will be compared. * after the second evaluation, both groups will be followed for 1 month and the same evaluations will be repeated. researchers will compare intervention and control groups to see executive functions and occupational participation.

autism spectrum disorder is a complex developmental disorder that can lead to dysfunctions in cognitive, emotion regulation, and communication skills. at the beginning of the cognitive problems seen in children with autism, the pathophysiology in executive functions, which is affected by individual differences, comes to the fore. difficulties related to executive functions such as cognitive flexibility and problem solving cause limitations in many basic areas, especially in daily life in autism. the cognitive orientation approach on daily occupational performance, designed by polatajko and others, is an activity-oriented problem-solving approach that uses cognitive strategies to develop motor skills in children who have difficulties during daily activities; it is a therapy method that focuses on the goal or the task itself, rather than the acquisition of functions within the activity performance. it is known that the approach is effective on social, emotional and organizational skills, especially cognitive skills in children with autism spectrum disorder.

Eligibility criteria:
inclusion criteria: * being diagnosed with autism spectrum disorder according to dsm-v by the department of child and adolescent mental health * being between the ages of 7 years and 10 years and 11 months * score 30-36 points on the childhood autism rating scale * participation must be approved by the parent. exclusion criteria: * having a concomitant neurological, psychiatric or orthopedic diagnosis * attending a program other than individual education

Keywords: autism spectrum disorder cognitive orientation ayres sensory integration
clinical application of 18f-pfpn pet imaging in diagnosis and staging of clear cell sarcoma of soft tissue

Conditions: Clear Cell Sarcoma of Soft Tissue

Summary: this study is a prospective monocentric study aimed to evaluate the diagnosis and staging value of 18f-pfpn pet in clear cell sarcoma of soft tissue. patients with clinically suspected or confirmed clear cell sarcoma of soft tissue will be recruited and 18f-pfpn pet/mr imaging will be performed. pet/ct imaging will be performed in patients with contraindications to mr. additionally, to compare the diagnostic efficacy with the traditional imaging agent 18f-fdg, patients will also undergo 18f-fdg pet imaging, and the two imaging intervals will be completed two days apart. the general information, clinical data, 18f-pfpn and 18f-fdg pet/mr or pet/ct imaging results and other imaging data of the patients will be collected. the histopathology of the biopsy or surgical specimen, follow-up and other imaging examinations will be taken as evaluation references. this study plans to set the sample size as 10 cases.

clear cell sarcoma of soft tissue is a rare malignancy derived from neural crest cells that contain melanin and/or melanin precursors. melanin is an important target for the diagnosis of clear cell sarcoma of soft tissue. 18f-pfpn, a highly specific melanin-targeting positron probe, has been proven to have excellent pharmacokinetic properties and good biological safety, and can sensitively detect tiny melanin-containing lesions. therefore, 18f-pfpn pet imaging is expected to be used in diagnosing and staging clear cell sarcoma of soft tissue. this study was designed as a prospective study to explore the diagnosis and staging value of 18f-pfpn pet in clear cell sarcoma of soft tissue. in this study, patients with clinically suspected or confirmed clear cell sarcoma of soft tissue will be recruited to undergo 18f-pfpn pet/mr imaging. pet/ct imaging will be performed in patients with contraindications to mr. the general information, clinical data, imaging data and histopathology results of patients will be collected. the efficiency of diagnosis and staging of 18f-pfpn was evaluated by comparing the gold standard pathological diagnosis and the general metabolic imaging agent 18f-fdg.

Eligibility criteria:
inclusion criteria: * adult patients (age 18 years or above), regardless of gender; * patients with clinically suspected or confirmed clear cell sarcoma of soft tissue (supporting evidence including visual examination, mri, ct, ultrasound, and histopathological examination, etc.) ; * patients who agree to undergo both 18f-pfpn and 18f-fdg pet imaging. exclusion criteria: * acute systemic diseases and electrolyte disturbances; * patients who plan to get pregnant within six months or are pregnant or breastfeeding; * the patient or his/her legal representative is unable or unwilling to sign the informed consent.
the effects of inspiratory muscle training in patients with heart failure and obstructive sleep apnea syndrome

Conditions: Chronic Heart Failure

Summary: this research aims to evaluate the effects of inspiratory muscle training (imt) on apnea hypopnea index, sleepiness, sleep quality, cognitive function, motor task, executive function, quality of life, chemoreflex sensitivity and vagal modulation of heart rate in patients with heart failure and obstructive sleep apnea syndrome.

patients with heart failure will be selected through the outpatient of the rio grande do sul, for convenience. subsequently, patients will be subjected to test respiratory muscle strength (manometer), respiratory muscle endurance, portable polysomnography, sleepiness, sleep quality, cognitive function (mini-mental state examination), motor task (execution of a sequence of digital movements), executive function, quality of life (sf-36), maximum exercise testing, chemoreflex sensitivity (peripheral chemoreflex by transient hypoxia and central chemoreflex by hypercapnic hyperoxia) and vagal modulation of heart rate (spectral analysis) before the start of the training protocol. patients will be randomized to inspiratory muscle training or control group. inspiratory muscle training will be performed for 30 minutes a day, 7 days a week, for 12 weeks with muscle training device (powerbreathe). there will be a weekly monitoring in the clinical research center of the institution where the maximal inspiratory pressure (mip) and respiratory training techniques will be reassessed and readjusted (30% of mip). the control group will be submitted to respiratory training techniques with muscle training device (powerbreathe) without load. after this period, all initial tests will be reassessed. a group study with 15 heart failure patients without obstructive sleep apnea syndrome will be included.

Eligibility criteria:
inclusion criteria: * heart failure patients with obstructive sleep apnea- hypopnea * heart failure patients without sleep apnea * left ventricle fraction ejection \< 51 % for men and \< 53% for woman * must be clinically stable * new york heart association i, ii and iii * without changes in medication for the last three months. exclusion criteria: * unstable angina * atrial fibrillation * acute myocardial infarction (\<6 months) * recent heart surgery (\<6 months) * chronic metabolic disease * infectious disease * anemia * severe hypoxemia * neuromuscular disease * diabetes mellitus * obesity * use of continuous positive airway pressure * smoking * pulmonary disease (forced vital capacity \<80% of predicted and / or forced expiratory volume in one second \<70% predicted).

Keywords: inspiratory muscle training heart failure obstructive sleep apnea
mbi for psychological distress, si and nssi among young adults

Conditions: Psychological Distress; Suicidal Ideation; Non-Suicidal Self Injury

Summary: designed to measure the impact of mindfulness based intervention on depression, anxiety, stress, psychological distress, suicidal ideation, non-suicidal self injury urge and mindfulness in young adults. those individuals who agree to participate in the trial and identified with high levels of psychological distress and suicidal ideation, randomly divided into interventional (n=30) and control (n=30) groups. the mindfulness based stress reduction intervention then administered to the interventional group for eight weeks and pre and post intervention assessment done for both the groups.

study assessment measures: * informed consent form * demographic questionnaire * screener questions form * assessment instruments: * depression anxiety and stress scale (dass-21) * suicide ideation scale (sis) * alexian brothers urge to self injure scale (abusi) * mindfulness attention awareness scale

Eligibility criteria:
inclusion criteria: * participants aged 18-24, of any gender, who consented to participate and could comprehend english (the language of the questionnaires). * selected respondents from the initial survey were included based on specific criteria: * willingness to continue participation. * unmarried status. * pursuing education (bachelors, masters, or ph.d.) , pakistan. * non-hosteller and unemployed. * residing with both parents. * affirmative response to screener questions about suicidal ideation (si) and non-suicidal self-injury (nssi). * high scores on psychological distress and si scales. exclusion criteria: * participants failing to meet inclusion criteria or falling under the following categories were excluded: * non-students. * history of present or past psychiatric illness, with recent medication or treatment within the past year. * presence of debilitating physical diseases or disabilities. involvement in or history of substance use. * long-term medication for any condition, as these factors could impact study results.

Keywords: mindfulness based intervention psychological distress suicidal ideation non-suicidal self injury
effect of myofascial release on dysphagia in parkinson's patients

Conditions: Parkinson Disease

Summary: the goal of this clinical trial is to explore clinical effect of myofascial release therapy in dysphagic parkinson's patients. the main question it aims to answer is: • can myofascial release therapy improve swallowing function in parkinson's patients? patients will be randomly allocated into the control group or the experimental group, all under rehabilitation treatment, the experimental group will be given myofascial release therapy. the study lasts 21 days for each patient. researchers will compare the functional oral intake scale, penetration-aspiration scale, swallowing quality of life to see if the myofascial release therapy can help improve the situation.

myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. it involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. the goal of this clinical trial is to explore clinical effect of myofascial release therapy in dysphagic parkinson's patients. the main question it aims to answer is: • can myofascial release therapy improve swallowing function in parkinson's patients? patients will be randomly allocated into the control group or the experimental group, all under rehabilitation treatment, the experimental group will be given myofascial release therapy. the study lasts 21 days for each patient. researchers will compare the functional oral intake scale, penetration-aspiration scale, swallowing quality of life to see if the myofascial release therapy can help improve the situation.

Eligibility criteria:
inclusion criteria: * age \>18 years. * meeting the diagnostic criteria for parkinson's disease. * diagnosed with dysphagia confirmed by the video fluoroscopic swallowing study. * water swallow test\> level 3. * stable vital signs, conscious, able to cooperate with assessment and treatment. exclusion criteria: * dysphagia possibly caused by other reasons, such as cerebrovascular disease, trauma, neuromuscular diseases, malignant diseases of the pharynx and larynx, and digestive tract diseases. * complicated with cognitive impairment or consciousness dysfunction. * simultaneously suffering from severe liver, kidney failure, tumors, or hematological diseases. * complicated with severe liver and kidney failure, tumors, or hematological disorders.
soy food and coronary heart disease in women

Conditions: Cardiovascular Diseases; Coronary Disease; Heart Diseases

Summary: to investigate whether soy food intake reduces risk of non-fatal myocardial infarction (mi) and fatal coronary heart disease in chinese women.

background: coronary heart disease (chd) is the leading cause of death in the us and many other countries. estrogen deficiency plays a significant role in the development of coronary heart disease (chd) in postmenopausal women. recently, a series of randomized clinical trials evaluating the effects of hormone replacement therapy (hrt) on chd yielded surprisingly deleterious results, shifting clinical decision-making from a position of presumed benefit to one of potential harm. soy food is emerging as a promising natural substitute for hrt, given its estrogenic properties and potential lipids benefits. however, data directly linking soy food intake to the clinical endpoints of chd are lacking. design narrative: the study will evaluate the association of soy food consumption with chd using resources from the shanghai women's health study (swhs), an ongoing prospective cohort study of 75,000 chinese women who were recruited from 1997 to 2000 and who completed two extensive dietary assessments at baseline. the investigators will verify all chd events identified in this cohort during the follow-up and longitudinally analyze the association between soy food intake and chd risk, overall, and according to conventional chd risk factors. in addition, they will conduct a nested case-control study to evaluate the association of urinary isoflavonoids (a biomarker of soy intake) and risk of chd, and to investigate whether soy and chd associations are modified by baseline levels of lipids and plasma c-reactive protein, two well established risk markers of chd. in the united states, the sale of soy products has increased more than 3-fold in recent decades, and the proportion of people reporting soy product consumption at least once a week nearly doubled in the last six years. however, the overall intake level of soy food in the us population is still low, and women who consume soy food regularly are likely to be highly selective. furthermore, it is difficult, if at all possible, to assess usual soy food intake in the us population because soy protein is added to many american food products. informative studies on the association between soy food intake and chd risk are better conducted in chinese and other asian populations, where soy food is part of traditional dietary practice. the swhs with its wealth of data on dietary and lifestyle factors and biological samples provides a unique and unparalleled opportunity to prospectively investigate the effects of soy food intake on the risk of chd, and to identify those most likely to benefit from consumption of soy food.

Eligibility criteria:
efficacy and safety of adalimumab 80 mg every other week with methotrexate

Conditions: Rheumatoid Arthritis

Summary: in japan, as well as in other countries, the dose of adalimumab (ada) is limited to 40 mg every other week when used in combination with methotrexate (mtx) for patients with rheumatoid arthritis (ra). however, ada 80 mg with mtx may be required for some ra patients, especially for those with high disease activity. therefore, we tried to increase the ada dose to 80 mg every other week with concomitant mtx, only if the disease activity did not decrease below moderate activity defined by das28 \< 3.2. the primary endpoint was the rate of patients who achieved disease remission (das28 \< 2.6) at 30 weeks with this predifined treatment strategy.


Eligibility criteria:
inclusion criteria: * patients with rheumatoid arthritis receiving mtx ≧ 6 mg/week for at least 3 months disease activity : das28 \> 5.1 exclusion criteria: * allergy to ada present active infection including tb history of demyelinating disease, hbv infection and malignancy
jiangzhuo qinggan prescription and irbesartan in the treatment of essential hypertension(hepatogastric damp-heat)clinical study

Conditions: Hypertension; Metabolic Syndrome

Summary: jangzhuo qinggan prescription and irbesartan in the treatment of essential hypertension(hepatogastric damp-heat), randomized, parallel-controlled, multi-center clinical study.

charged by the five research centers in line with traditional chinese medicine hepatogastric damp-heat syndrome 240 cases have hypertension, and overweight, as well as blood lipid disorders or diabetes were randomly divided into chinese herbal compound jiangzhuo qinggan prescription group and western medicine irbesartan group.the treatment groups were compared 4-week step-down and regulation of blood lipids, blood sugar effect.

Eligibility criteria:
inclusion criteria: 1. consistent with diagnosed hypertension, blood pressure, for 1-2 grade. 2. aged 18-65 years old. 3. body mass index (bmi) ≥ 24kg/m2, but \<35 kg/m2. 4. waist circumference ≥ 85cm (male) or waist circumference ≥ 80cm (women). 5. comply with any of the following 3 : triglyceride (tg) elevated levels of:\> 150mg/dl (1.7mmol / l), or has received appropriate treatment; high-density lipoprotein - cholesterol (hdl-c) levels reduced: men \<40mg/dl (0.9mmol / l), women \<50mg/dl (1.1mmol / l), or has received appropriate treatment; fasting plasma glucose (fpg) increased: fpg ≥ 100mg/dl (5.6mmol / l ), or previously diagnosed type 2 diabetes or have received appropriate treatment. 6. hepatogastric damp-heat syndrome differentiation. 7. to sign informed consent. exclusion criteria: 1. has been used to control lipids, blood sugar drugs, but use the time for those below the 1 month. 2. nearly 3 months, weight loss ≥ 5%. 3. suffering from congenital heart disease, rheumatic heart disease, congestive heart failure, unstable angina, and had a myocardial infarction, percutaneous transluminal coronary angioplasty (ptca) or off-line clinical significance of arrhythmia. 4. bilateral renal artery stenosis, solitary kidney, serum creatinine\> 133μmol / l . 5. active liver disease, history of chronic persistent hepatitis, alt\> upper limit of normal. 6. peptic ulcer or malabsorption syndrome . 7. with insulin-treated diabetes. 8. there is a history of appetite or abuse of laxatives by hyperthyroidism. 9. pregnancy, pregnancy or breast-feeding women to prepare. 10. for those who are allergic chinese medicine, allergic people. 11. mentally ill. 12. hyperkalemia in patients. 13. cancer. 14. occurred within the past 6 months who had a stroke or transient ischemic attack (tia). 15. nearly 3 months in patients receiving other clinical studies. 16. alcohol and / or psychoactive substances, drug abuse and dependency.

Keywords: chinese herbs
cobalt chromium stent with antiproliferative for restenosis ii trial (costar ii)

Conditions: Coronary Disease

Summary: the purpose of this study is to evaluate the safety and effectiveness of the investigational stent costar™ paclitaxel-eluting coronary stent- a reservoir based des system in comparison to a surface coated des stent (taxus™ express2™ paclitaxel-eluting coronary stent) in the treatment of single-vessel (one blood vessel) and multi-vessel (two or three blood vessels) coronary artery disease.

non -inferiority in 8-month major adverse cardiac events (mace) and in-segment late lumen loss at 9 months between the costar™ paclitaxel-eluting coronary stent system and the taxus™ express2™ drug eluting coronary stent system for the treatment of a single de novo lesion per vessel in patients with single and multi-vessel coronary disease.

Eligibility criteria:
inclusion criteria: general inclusion criteria: * eligible for percutaneous coronary intervention (pci) * documented stable or unstable angina pectoris (class i, ii, iii or iv), documented ischemia, or documented silent ischemia * documented lvef ≥25% within the last 6 weeks. * eligible for coronary artery bypass graft surgery (cabg) exclusion criteria: general exclusion criteria: * known sensitivity to paclitaxel or polymeric matrices: translute or plga. * planned treatment with any other pci device in the target vessel(s). * mi within 72 hours prior to the index procedure * patient is in cardiogenic shock * cerebrovascular accident (cva) within the past 6 months * acute or chronic renal dysfunction (creatinine \>2.0 mg/dl or \>150 µmol/l) * contraindication to asa or to clopidogrel * thrombocytopenia * active gi bleeding within past three months * known allergy to stainless steel or cobalt chromium * any prior true anaphylactic reaction to contrast agents * patient is currently taking colchicine

Keywords: percutaneous coronary intervention (pci) drug eluting stent (des)